Omeros Financing Extending Maturity on a Majority of Debt into 2028

 

• $118.1 million, or 55%, of outstanding convertible notes due in 2026 repurchased at approximately 75% of notional value, resulting in $51 million in total debt extinguishment
• Repurchase funded from new $67 million secured four-year term loan maturing in June 2028 together with $21 million cash on hand
• Credit facility includes $25 million delayed draw term loan conditionally available to fund narsoplimab commercialization
• Transactions include no equity component, preventing shareholder dilution, and enable additional debt reduction

https://www.businesswire.com/news/home/20240603889120/en/Omeros-Corporation-Further-Strengthens-its-Balance-Sheet-through-Series-of-Financing-Transactions-Extending-Maturity-on-a-Majority-of-its-Outstanding-Debt-into-2028